Jordyn Sava is an editor for Targeted Oncology.
After preclinical and early clinical studies show promising data with CTX-009 therapy, a phase 2 study of the agent has dosed its first patient with metastatic colorectal cancer.
In an interview with Targeted Oncology, Gustavo Fonseca, MD, FACP, discussed the positive health-related quality of life findings in patients with diffuse large B-cell lymphoma from the POLARIX study.
According to The Cancer Genome Atlas and the ProMisE algorithm, there are 4 molecular subtypes of endometrial cancer, including POLE, dMMR, p53 abnormal, and no specific molecular profile.
Patients with small cell lung cancer will receive diagnostic and post-progression tumor tissue profiling, plasma ctDNA biomarker profiling, standard of care therapy, and disease surveillance in the Sculptor study.
While upfront transplant showed benefit vs carfilzomib, cyclophosphamide, and dexamethasone in the phase 2 CARDAMON study of patients with multiple myeloma, 57.7% of patients achieved at least a very good partial response with the combination.
Based on data from a phase 1/2 study, a biologics license application has been accepted for glofitimab and the product has been granted priority review to for relapsed/refractory large B-cell lymphoma.
In an interview with Targeted Oncology, Cyrus M. Khan, MD, further discussed the background of the phase 1/2 trial and the potential use of glofitamab for patients with large B-cell lymphoma in the future.
In the diffuse large B-cell lymphoma and follicular lymphoma cohorts of the ELM-1 and ELM-2 trials, odronextamab led to high overall response rates.
A phase 1/2 study of uproleselan combined with chemotherapy led to a complete response of 35% and median overall survival of 8.8 months in a cohort of patients with relapsed/refractory acute myeloid leukemia.
Based on findings from a phase 1 study, the FDA has received a biologics license application for cosibelimab for patients with advanced or metastatic cutaneous squamous cell carcinoma.
The THUNDER case-control study elicited a 69.1% rate of sensitivity and 98.9% rate of specificity with the OverC™ MCDBT in adult patients with various cancers.
The combination of PDS0101, M9241, and bintrafusp alfa elicited a promising median overall survival in patients with checkpoint inhibitor refractory advanced human papillomavirus-positive cancers.
A prospective, blinded study confirmed the accuracy of the detecting brain tumors with the TriNetraTM-Glio test, addressing an unmet medical need for experts in this space.
In December 2022, the FDA granted 5 approvals, 2 breakthrough therapy designations, 1 fast track designation, lifted a clinical hold, cleared an investigational new drug application, and more.
In an interview with Targeted Oncology, Justin Taylor, MD, discussed the recent changes that have been seen with this new classification of MDS and how this review article can help make people more aware of the treatment options available.
In an interview with Targeted Oncology, Jimmy Caudell, MD, PhD, discussed the biggest challenges being faced in the head and neck cancer space.
In an interview with Targeted Oncology, Marc S. Ernstoff, MD, discusses recent updates in the management of metastatic melanoma.
In an interview with Targeted Oncology, Allan Pickens, MD, discussed research on racial disparities in surgery for esophageal cancer.
In an interview with Targeted Oncology, Jay W. Granzow, MD, discussed the diagnosis and early detection of patients with cancer-related secondary lymphedema.
In an interview with Targeted Oncology, Channing J. Paller, MD, discussed the current approaches to radiation therapy, androgen deprivation therapy, and molecular imaging for men with prostate cancer who have biochemical recurrence.
Treatment with CD19-/CD22-chimeric antigen T-cell therapy demonstrated durable remissions in children with relapsed or refractory B-acute lymphoblastic leukemia, according to a phase 2 study.
For patients with locally advanced or metastatic urothelial cancer, the FDA has accepted for priority review supplemental biologics license applications for enfortumab vedotin-ejfv and pembrolizumab.
In an interview with Targeted Oncology, Martin Dreyling, MD, discussed the implications of the findings from the TRIANGLE study in patients with mantle cell lymphoma.
Based on findings from the DESTINY-Gastric01 and -02 trials, the European Commission has approved fam-trastuzumab deruxtecan-nxki monotherapy for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Data from the phase 3 PEARL study show that durvalumab does not induce statistically significant overall survival in patients with metastatic non–small cell lung cancer.
The GLOW trial of zolbetuximab plus capecitabine and oxaliplatin showed statistically significant progression-free and overall survival rates in CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
In an interview with Targeted Oncology, Marlise Luskin, MD, MSCE, discussed the challenges of treating adult and elderly patients with acute lymphoblastic leukemia and where new research in the space is headed.
Findings from 3 studies show that treatment with plinabulin elicits efficacy and reduces the duration of severe neutropenia in patients with non–small cell lung cancer receiving docetaxel.
In an interview with Targeted OncologyTM, Evan Y. Yu, MD, discusses data from the KEYLYNK-010 trial and the future of the combination in prostate cancer.
A safety review committee has approved the Acclaim-1 trial of ozeplasmid plus osimertinib in non–small cell lung cancer to move on to the third cohort of the study.